VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, which discusses the potential of the Nu.Q H3.1 test in managing sepsis patients.
According to Volition, multiple studies have demonstrated that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Most of the supporting research has been peer-reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations.
The company believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs, and early detection and monitoring are critical for improving patient outcomes.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, the company is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For further information, visit the company's website at https://volition.com/. The full press release can be viewed at https://ibn.fm/2IH3m.
